Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a novel peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in a global pivotal Phase 3 trial and in three additional supporting clinical trials. Oncopeptides’ headquarters is located in Stockholm, Sweden and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
View Top Employees from Oncopeptides ABWebsite | http://www.oncopeptides.se |
Revenue | $83 million |
Employees | 83 (83 on RocketReach) |
Founded | 2000 |
Address | Luntmakargatan 46, vån 7, Stockholm, Stockholm 111 37, SE |
Phone | (468) 615-2040 |
Technologies | |
Industry | Pharmaceuticals, Multiple Myeloma, Healthcare, Melflufen, Drug Manufacturing & Research, Plasma Cell Myeloma, Biotechnology, Orphan Drug, Relapsed & Relapsed-Refractory Multiple Myeloma, Peptidase Potentiated, Anti-Angiogenic, Cytotoxicity, Alkylation, Peptidase Targeting, Phase II, Efficacy Studies, Oncology |
Web Rank | 6 Million |
Keywords | Oncopeptides, Oncopeptides Investor Relations, Alkylerare Verkningsmekanism, .Se, Oncopeptides Management Bourse |
Competitors | Corbus Pharmaceuticals, CrystalGenomics, Inc., Embera NeuroTherapeutics, GlycoMimetics, OxThera |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Oncopeptides AB employee's phone or email?
The Oncopeptides AB annual revenue was $83 million in 2023.
Eva Nordström is the COO of Oncopeptides AB.
83 people are employed at Oncopeptides AB.
Oncopeptides AB is based in Stockholm, Stockholm.
The NAICS codes for Oncopeptides AB are [32, 3254, 32541, 325].
The SIC codes for Oncopeptides AB are [283, 28].